FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000722847> ?p ?o ?g. }

• W2000722847 endingPage "349" @default.
• W2000722847 startingPage "344" @default.
• W2000722847 abstract "We report 2 children with X-linked chronic granulomatous disease (X-CGD) who underwent hematopoietic stem cell transplantation (HSCT) using grafts from their siblings selected before implantation to be both unaffected and HLA-matched donors. Preimplantation genetic diagnosis (PGD) along with HLA-typing were performed on preimplantation embryos by single-cell multiplex polymerase chain reaction using informative short tandem repeat markers in the HLA locus together with the gene region containing the mutations. Two singleton pregnancies resulted from the intrauterine transfer of selected embryos; these developed to term, producing 1 healthy female and 1 X-CGD carrier female, which are HLA-identical siblings to the 2 affected children. Combined grafts of umbilical cord blood (UCB) and bone marrow (BM) stem cells were administered to the recipients after myeloablative (MA) conditioning at the ages of 4.5 years and 4 years, respectively. Both patients are well, with complete donor hematopoietic and immunologic reconstitution, at 18 and 13 months posttransplantation, respectively. This report demonstrates that HSCT with HLA-matched sibling donors created by PGD/HLA typing of in vitro fertilized embryos is a realistic therapeutic option and should be presented as such to families with children who require a non-urgent HSCT but lack an HLA-genoidentical donor. We report 2 children with X-linked chronic granulomatous disease (X-CGD) who underwent hematopoietic stem cell transplantation (HSCT) using grafts from their siblings selected before implantation to be both unaffected and HLA-matched donors. Preimplantation genetic diagnosis (PGD) along with HLA-typing were performed on preimplantation embryos by single-cell multiplex polymerase chain reaction using informative short tandem repeat markers in the HLA locus together with the gene region containing the mutations. Two singleton pregnancies resulted from the intrauterine transfer of selected embryos; these developed to term, producing 1 healthy female and 1 X-CGD carrier female, which are HLA-identical siblings to the 2 affected children. Combined grafts of umbilical cord blood (UCB) and bone marrow (BM) stem cells were administered to the recipients after myeloablative (MA) conditioning at the ages of 4.5 years and 4 years, respectively. Both patients are well, with complete donor hematopoietic and immunologic reconstitution, at 18 and 13 months posttransplantation, respectively. This report demonstrates that HSCT with HLA-matched sibling donors created by PGD/HLA typing of in vitro fertilized embryos is a realistic therapeutic option and should be presented as such to families with children who require a non-urgent HSCT but lack an HLA-genoidentical donor. IntroductionX-linked chronic granulomatous disease (X-CGD) is an inherited defect in phagocyte nicotinamide adenine dinucleotide phosphate oxidase resulting from a deficiency of gp91phox component. At the molecular level, X-CGD is caused by mutations affecting the CYBB gene on chromosome Xp21.1 [1Heyworth P.G. Cross A.R. Curnutte J.T. Chronic granulomatous disease.Curr Opin Immunol. 2003; 15: 578-584Crossref PubMed Scopus (332) Google Scholar, 2Segal B.H. Leto T.L. Gallin J.I. et al.Genetic, biochemical, and clinical features of chronic granulomatous disease.Medicine (Baltimore). 2000; 79: 170-200Crossref PubMed Scopus (720) Google Scholar]. As a result of impaired phagocytic ability, affected persons suffer from severe recurrent infections, both bacterial and fungal, resulting in the formation of infiltrating granulomatous lesions. Despite prophylactic therapy, long-term survival remains poor; only 50% of patients are alive at the age of 30 years [3Van den Berg J.M. van Koppen E. Ǻhlin A. et al.Chronic granulomatous disease: The European experience.PLoS ONE. 2009; 4 (e5234:1–10)Crossref Scopus (497) Google Scholar, 4Winkelstein J.A. Marino M.C. Johnston Jr., R.B. et al.Chronic granulomatous disease. Report on a national registry of 368 patients.Medicine (Baltimore). 2000; 79: 155-169Crossref PubMed Scopus (1223) Google Scholar]. Allogeneic hematopoietic stem cell transplantation (HSCT) using an HLA-matched sibling donor (MSD) has achieved long-term cure of X-CGD in 80% to 90% of cases [5Seger R.A. Güngor T. Belohradsky B.H. et al.Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000.Blood. 2002; 100: 4344-4350Crossref PubMed Scopus (226) Google Scholar, 6Seger R.A. Modern management of chronic granulomatous disease.Br J Haematol. 2008; 140: 255-266Crossref PubMed Scopus (194) Google Scholar]. A healthy MSD is not available in the vast majority of the cases, however. For such patients, a matched unrelated donor (MUD) is a suitable option, but at the cost of increased teatment-related morbidity and mortality (TRM) [5Seger R.A. Güngor T. Belohradsky B.H. et al.Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000.Blood. 2002; 100: 4344-4350Crossref PubMed Scopus (226) Google Scholar, 7Del Giudice I. Iori A.P. Mengarelli A. et al.Allogeneic stem cell transplant from HLA-identical sibling for chronic granulomatous disease and review of the literature.Ann Hematol. 2003; 82: 189-192PubMed Google Scholar]. Preimplantation genetic diagnosis (PGD) for single-gene diseases was developed to help families desiring a new pregnancy to select unaffected embryos in vitro, thereby avoiding the need for pregnancy termination. Recently, this strategy has been combined with HLA typing with the aim of selecting suitable histocompatible embryos as potential stem cell donors for affected siblings [8Fiorentino F. Biricik A. Karadayi H. et al.Development and clinical application of a strategy for preimplantation genetic diagnosis of single gene disorders combined with HLA matching.Mol Hum Reprod. 2004; 10: 445-460Crossref PubMed Scopus (70) Google Scholar, 9Van de Velde H. Georgiou I. De Rycke M. et al.Novel universal approach for preimplantation genetic diagnosis of β-thalassemia in combination with HLA matching of embryos.Hum Reprod. 2004; 19: 700-708Crossref PubMed Scopus (92) Google Scholar, 10Kuliev A. Rechitsky S. Tur-Kaspa I. et al.Preimplantation genetics. Improving access to stem cell therapy.Ann N Y Acad Sci. 2005; 1054: 223-227Crossref PubMed Scopus (47) Google Scholar]. There is limited experience with this methodology and even less with its completed clinical application, however.MethodsPatient CharacteristicsPatient 1In this 4.5-year-old boy with an established diagnosis of X-CGD since infancy, diagnosis was confirmed by respiratory burst screening tests and by DNA CYBB gene sequencing (R73X C → T mutation). Despite both antimicrobial and interferon-γ prophylaxis, the patient had recurrent infections from the age of 4 months onward, and granulomatous colitis was diagnosed at the age of 1.7 years.Patient 2This 4-year-old boy was diagnosed with X-CGD at age 6 months by both functional and molecular tests (R157X C → T mutation). Before presenting for HSCT, he had experienced multiple cervical abscesses despite receiving antibiotic prophylaxis.Donor SelectionNeither patient had an HLA-genoidentical sibling donor. The patients' parents came to the Diagnostic Genetic Centre in Athens on their own initiative for genetic consultation. After detailed genetic counseling, the couples came to the Centre for Human Reproduction, Genesis Athens Hospital for complete counseling regarding in vitro fertilization (IVF) and embryo biopsy procedures. The clinical protocol was approved by the center's Institutional Research and Ethics Committee for the IVF treatment, embryo biopsy, and PGD procedures required for the transfer of unaffected and HLA-identical embryos to the mother's uterus. Written informed consent concerning the PGD/HLA typing procedure, as well as the cryopreservation of nontransferred embryos for future use, in accordance with the Helsinki Declaration, was obtained from both couples. A single cycle of IVF was initiated for each couple, and standard hormonal stimulation and culture techniques were used to generate embryos for PGD and HLA genotyping [11Pantos K. Meimeth-Damianaki T. Vaxevanoglou T. et al.Prospective study of a modified gonadotropin-releasing hormone agonist long protocol in an in vitro fertilization program.Fertil Steril. 1994; 61: 709-713PubMed Scopus (37) Google Scholar, 12Palermo G. Joris H. Devroey P. et al.Pregnancies after intracytoplamic injection of single spermatozoon into an oocyte.Lancet. 1992; 340: 17-18Abstract PubMed Scopus (2874) Google Scholar]. All fertilized embryos were cultured and biopsied by laser on day 3 in the first couple and on day 5 for the second couple [13Kokkali G. Traeger-Synodinos J. Vrettou C. et al.Blastocyst biopsy versus cleavage stage biopsy and blastocyst transfer for preimplantation diagnosis of β-thalassemia: a pilot study.Hum Reprod. 2007; 22: 1443-1449Crossref PubMed Scopus (118) Google Scholar]. Embryo genotyping was performed using a nested multiplex polymerase chain reaction (PCR) approach, involving first- and second-round amplification of the informative polymorphic short tandem repeat (STR) markers previously selected by extensive HLA genotyping and haplotype analysis of the family members. Detection of the disease mutation was performed by minisequencing [14Pangalos C.G. Hagnefelt B. Kokkali G. et al.Birth of a healthy histocompatible sibling following preimplantation genetic diagnosis for chronic granulomatous disease at the blastocyst stage coupled to HLA typing.Fetal Diagn Ther. 2008; 24: 334-339Crossref PubMed Scopus (11) Google Scholar]. Embryos identified to be HLA-identical to the patients and unaffected by X-CGD (homozygous wild-type allele or heterozygous mutation) were transferred 6 days after fertilization to the uterus of the respective mothers. The 2 singleton full-term pregnancies resulted in the birth of 1 healthy and 1 X-CGD carrier female siblings. Confirmatory genetic testing was performed using chorionic villus sampling in the first trimester for CGD mutations and HLA typing. To rule out the possibility of extreme inactivation of the X chromosome in the case of the heterozygotic sibling donor carrying the nonmutated CYBB, postnatal neutrophil superoxide production was measured.HSCTUmbilical cord blood (UCB) was collected, frozen, and stored in liquid nitrogen as described previously [15Rubinstein P. Dobrila L. Rosenfield R.E. et al.Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution.Proc Natl Acad Sci USA. 1995; 92: 10119-10122Crossref PubMed Scopus (706) Google Scholar]. Given the limited experience with UCB transplantation (UCBT) in patients with X-CGD, we decided to combine UCB and bone marrow (BM) HSC from the same donors, to ensure stable long-term engraftment. Therefore, after parental written consent was provided, when the 2 sibling donors reached age 16 months, reduced-volume BM was harvested. Both patients were conditioned with busulfan (Bu; 16 mg/kg i.v) and cyclophosphamide (Cy; 200 mg/kg i.v.). Graft-versus-host disease (GVHD) prophylaxis comprised cyclosporine A and a short course of methotrexate (MTX). Time to white blood cell engraftment was defined as the first of 3 consecutive days with a neutrophil count > 0.5 × 109/L, and platelet engraftment was defined as the first of 3 consecutive days on which a platelet count > 20 × 109/L was maintained without transfusion. To assess engraftment and the degree of chimersm, patients were monitored at different time points, using a PCR assay to identify genetic polymorphism of STRs. Superoxide production by neutrophils was measured by the dihydrorhodamine (DHR) test. Expression of gp91phox on neutrophils was measured using the 7D5 monoclonal antibody (mAb) and flow cytometry.ResultsPGD/HLA Typing of EmbryosEach family was subjected to a single clinical IVF cycle. A total of 48 embryos were tested for the 2 couples. Eight of these embryos were diagnosed as unaffected and HLA-matched, and 2 embryos from each cycle were transferred, resulting in 2 singleton pregnancies and 2 newborns, 1 healthy and 1 X-CGD carrier. All X-CGD–unaffected embryos not transferred were cryopreserved for eventual future use. Table 1 summarizes the PGD/HLA typing results.Table 1Summary of the PGD/HLA typing resultsFamilyIVF CycleEmbryos FormedHLA-Matched, CGD-Unaffected EmbryosEmbryos TransferredPregnancies11376∗Four embryos were homozygous for the wild-type allele.2121112†Both embryos were carriers for the CGD mutation.21PGD indicates preimplantation genetic disease; CGD, chronic granulomatous disease. Biopsies were performed at the cleavage stage (day 3 after fertilization) for family 1 and at the blastocyst stage (day 5 after fertilization) for family 2.∗ Four embryos were homozygous for the wild-type allele.† Both embryos were carriers for the CGD mutation. Open table in a new tab Graft CharacteristicsThe numbers of UCB-nucleated and CD34+ cells collected from the first donor (1.4 × 107/kg and 3.5 × 104/kg, respectively) were deemed insufficient to secure long-term engraftment. Therefore, we decided to increase the number of hematopoietic progenitors by harvesting a reduced BM volume from the same donor. In the case of second donor, and despite an adequate number of cells in the UCB unit, we decided to harvest a small volume (100 mL) of BM to further enrich the number of hematopoietic progenitors. Coinfusion of BM cells in the second case was chosen because of the extremely limited experience with matched related UCBT in X-CGD and the high risk of graft failure reported in small series of children undergoing unrelated UCBT [16Parikh S.H. Szabolcs P. Prasad V.K. et al.Correction of chronic granulomatous disease after second unrelated donor umbilical cord blood transplantation.Pediatr Blood Cancer. 2007; 49: 982-984Crossref PubMed Scopus (25) Google Scholar]. In both cases, BM was harvested when the donors reached the age of 16 months. Details on the number of nucleated and progenitor cells of the grafts are given in Table 2.Table 2Characteristics of patients, donors, and grafts, and transplantation outcomePatient 1Patient 2Age, years4.54SexMaleMaleDonor sexFemaleFemaleX-CGD carrier donorNoYesUCB volume collected, mL112143UCB nucleated cells/kg1.4 × 10710 × 107UCB CD34+ cells/kg0.35 × 1052.8 × 105BM volume collected, mL174100BM nucelated cells/kg3.2 × 1083 × 108BM CD34+ cells/kg13.6 × 1067.5 × 106Neutrophil engraftmentDay +20Day +18Platelet engraftmentDay +19Day +17GVHDNoNoChimerismFull donorFull donorCGD indicates chronic granulomatous disease; UCB, umbilical cord blood; BM, bone marrow; GVHD, graft-versus-host disease. Open table in a new tab Transplantation OutcomeBoth patients engrafted quickly after receiving a combined graft of UCB and BM cells. Neutrophil engraftment was achieved on day +20 in patient 1 and on day +18 in patient 2, and platelet engraftment occurred on days +19 and +17, respectively. Complete donor-derived hematopoietic chimerism was repeatedly detected after day +60 posttransplantation by studying STRs. Neither patient developed acute or chronic graft-versus-host disease (aGVHD, cGVHD). Cyclosporine (CsA) and replacement i.v. immunoglobulin were stopped at 6 months posttransplantation. Patient 1 had normal stools since day +30 posttransplantation, indicating resolution of colitis. In patient 1, both DHR and gp91phox expression were restored to normal on 100% of the neutrophils posttransplantation, whereas in patient 2, only 50% of neutrophils exhibited normal DHR and gp91phox expression posttransplantation. Repeated testing revealed similar results at various time intervals posttransplantation (Figure 1). At their last follow-up visit, both patients were in excellent clinical condition, demonstrating normal hematopoietic and immunologic reconstitution at 18 and 13 months posttransplantation, respectively.DiscussionThe practice of conceiving an additional child with the intention of using it as an HSC donor for an affected sibling has been done for many years [17Kearney W. Kaplan A.L. Parity for the donation of bone marrow: Ethical and policy consideration.in: Blank R.H. Bonnicksen A.L. Emerging Issues in Biomedical Ethics. An annual review. Vol I.. Columbia University Press, New York1993: 262-285Google Scholar]. In the early years, parents planned to have another child by natural conception and hoped for an HLA-matching sibling. More recently, Verlinsky et al. [18Verlinsky Y. Rechtisky S. Schoolcraft W. et al.Preimplantation diagnosis for Fanconi anemia combined with HLA-matching.JAMA. 2001; 285: 3130-3133Crossref PubMed Scopus (319) Google Scholar] reported HLA typing combined with PGD in a case of Fanconi anemia. Although only 3/16 embryos for X-linked recessive inheritance will be both disease-free and HLA-identical, the likelihood of conceiving a matched donor using PGD/HLA typing is much greater than that with a spontaneous conception. Only a limited number of PGD centers offering HLA typing on human preimplantation embryos exist worldwide, limiting experience with the combination of IVF and PGD to achieve pregnancy and birth of a healthy HLA-compatible sibling. Published data from different series worldwide have reported 64 children born after PGD/HLA testing; the pregnancy rate per embryo transfer was 34% on average, varying depending on the IVF center and age of the mother [10Kuliev A. Rechitsky S. Tur-Kaspa I. et al.Preimplantation genetics. Improving access to stem cell therapy.Ann N Y Acad Sci. 2005; 1054: 223-227Crossref PubMed Scopus (47) Google Scholar, 19Van de Velde H. De Rycke M. De Man C. et al.The experience of two European preimplantation genetic diagnosis centres on human leukocyte antigen typing.Hum Reprod. 2009; 24: 732-740Crossref PubMed Scopus (47) Google Scholar, 20Samuel G.N. Strong K.A. Kerridge I. et al.Establishing the role of pre-implantation genetic diagnosis with human leukocyte antigen typing: what place do “saviour siblings” have in paediatric transplantation?.Arch Dis Child. 2009; 94: 317-320Crossref PubMed Scopus (31) Google Scholar]. All 64 children were healthy and HLA-identical to their affected siblings. In these series, only 12 transplantations leading to the cure of affected siblings have been reported [19Van de Velde H. De Rycke M. De Man C. et al.The experience of two European preimplantation genetic diagnosis centres on human leukocyte antigen typing.Hum Reprod. 2009; 24: 732-740Crossref PubMed Scopus (47) Google Scholar, 21Grewal S.S. Kahn J.P. MacMillan M.L. et al.Successful hematopoietic stem cell transplantation for Fanconi anemia from unaffected HLA-genotype-identical sibling selected using preimplantation genetic diagnosis.Blood. 2004; 103: 1147-1151Crossref PubMed Scopus (115) Google Scholar, 22Bielorai B. Hughes M.R. Auerbach A.D. et al.Successful umbilical cord blood transplantation for Fanconi anemia using pre-implantation genetic diagnosis for HLA-matched donor.Am J Hematol. 2004; 77: 397-399Crossref PubMed Scopus (38) Google Scholar]. Although no mistakes on HLA typing have been reported so far, the possibility of misdiagnosis of either HLA typing or PGD resulting from technical and human errors cannot be excluded [19Van de Velde H. De Rycke M. De Man C. et al.The experience of two European preimplantation genetic diagnosis centres on human leukocyte antigen typing.Hum Reprod. 2009; 24: 732-740Crossref PubMed Scopus (47) Google Scholar, 23Wilton L. Thornhill A. Traeger-Synodinos J. et al.The causes of misdiagnosis and adverse outcomes in PGD.Hum Reprod. 2009; 24: 1221-1228Crossref PubMed Scopus (169) Google Scholar]. Therefore, it must be made clear to the family that prenatal diagnosis is an absolute requirement to rule out an affected pregnancy. In addition, the use of this method raises a number of practical and ethical issues, such as the creation of human beings solely for instrumental use, most of which can be addressed by careful genetic and psychological counseling of the parents [24Pennings G. Scots R. Liebers I. Ethical considerations on preimplantation genetic diagnosis for HLA typing to match a future child as a donor of haematopoietic stem cells to a sibling.Hum Reprod. 2002; 17: 534-538Crossref PubMed Scopus (108) Google Scholar, 25Fost N.C. Conception for donation.JAMA. 2004; 291: 2125-2126Crossref PubMed Scopus (20) Google Scholar, 26De Wert Q. Liebers I. Van de Velde H. The future (r)evolution of preimplantation genetic diagnosis/human leukocyte antigen testing: Ethical reflections.Stem Cells. 2007; 25: 2167-2172Crossref PubMed Scopus (23) Google Scholar]. Other significant open issues remain, including the fate of unused healthy HLA-nonidentical embryos that greatly exceed the number created to address infertility. The law on medically assisted reproduction should provide regulations regarding the use of PGD/HLA typing and determine the fate of unused healthy embryos. In some countries, regulations permit the transfer of selected embryos based on HLA typing in combination with PGD, whereas in others this is not allowed. Clearly, further research is required to elucidate the clinical, social, psychological, and economic issues that might be relevant to the application of this technology.Although infusion of autologous HSC genetically modified to express gp91phox has been associated with some transitory benefits in a few patients, the safety and efficacy of gene therapy in X-CGD remain of major concern [27Malech H.L. Maples P.B. Whiting-Theobald N. et al.Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease.Proc Natl Acad Sci USA. 1997; 94: 12133-12138Crossref PubMed Scopus (287) Google Scholar, 28Ott M.G. Schmidt M. Schwarzwaelder K. et al.Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1.Nat Med. 2006; 12: 401-409Crossref PubMed Scopus (974) Google Scholar]. Currently, allogeneic HSCT from an HLA-matched donor is the only therapeutic modality with curative potential for patients with X-CGD. Allogeneic HSCT is best performed at an early age in children with recurrent serious infections despite antimicrobial prophylaxis [6Seger R.A. Modern management of chronic granulomatous disease.Br J Haematol. 2008; 140: 255-266Crossref PubMed Scopus (194) Google Scholar, 29Kang E.M. Malech H.L. Advances in treatment for chronic granulomatous disease.Immunol Res. 2009; 43: 77-84Crossref PubMed Scopus (35) Google Scholar]. A recent study of the efficacy of allogeneic HSCT in 20 patients with X-CGD found that the type of donor (MSD or MUD) had no effect on transplantation outcome [30Soncini E. Slatter M.A. Jones L.B.K.R. et al.Unrelated donor and HLA-identical sibling haematopoietic stem cell transplantation cure chronic granulomatous disease with good long-term outcome and growth.Br J Haematol. 2009; 145: 73-83Crossref PubMed Scopus (96) Google Scholar]. It is obvious, however, that the efficacy and safety of MUD-HSCT should be examined in larger cohorts of patients. Moreover, a MUD is available for only 60% to 70% of the patients in need of a donor, possibly even lower in patients of ethnic minorities [31Rocha V. Locatelli F. Searching for alternative hematopoietic stem cell donors for pediatric patients.Bone Marrow Transplant. 2008; 41: 207-214Crossref PubMed Scopus (135) Google Scholar]. Experience with either related or unrelated UCB as the source of HSC for patients with X-CGD is very limited, and only a few cases have been reported so far [32Mochizuki K. Kikuta A. Ito M. et al.Successful unrelated cord blood transplantation for chronic granulomatous disease: a case report and review of the literature.Ped Transplant. 2009; 13: 384-389Crossref PubMed Scopus (17) Google Scholar].Following the recently published first case report of successful HSCT of an X-linked-CGD patient using preimplantation female sex typing and HLA-typing [33Reichenbach J. Van de Velde H. De Rycke M. et al.First successful bone marrow transplantation for X-linked chronic granulomatous disease by using preimplantation female gender typing and HLA matching.Pediatrics. 2008; 122: e778-e782Crossref PubMed Scopus (22) Google Scholar], we describe 2 additional patients who underwent successful transplantation from a matched healthy sibling preselected by combined PGD and HLA typing. We chose to use PGD rather than female gender selection to detect the disease-specific mutation, to preclude the rejection of unaffected male embryos that cannot be differentiated from those affected when using fluorescein in situ hybridization (FISH) for female sex typing.PGD/HLA typing technology should be considered and discussed with parents in cases where no suitable MSD is available and transplantation using an unrelated donor either carries significantly higher risks than the use of a sibling donor or is not possible because of the unavailability of a suitable MUD. The foregoing methodology can be applied in patients requiring nonurgent HSCT, such as patients with a genetic disease or children who may require transplantation in the future because of progression of an underlying disease, such as acute lymphoblastic leukemia ALL) in first complete remission (CR1) (20Samuel G.N. Strong K.A. Kerridge I. et al.Establishing the role of pre-implantation genetic diagnosis with human leukocyte antigen typing: what place do “saviour siblings” have in paediatric transplantation?.Arch Dis Child. 2009; 94: 317-320Crossref PubMed Scopus (31) Google Scholar). In addition, the parents of the affected child still must be in reproductive age. Before making any decision, parents should be informed about the efficacy and safety of all alternative options, such as allogeneic HSCT using an MUD or an unrelated UCB unit. Parents also should be informed about the possibility of using BM or reduced-volume BM plus UCB, as in our patients reported here, especially when insufficient UCB cells are available. A high cell dose (> 3.7 × 107/kg) is considered crucial to sustain engraftment in patients with nonmalignant diseases undergoing MRD-UCBT [34Rocha V. Chastang C. Souillet G. et al.Related cord blood transplants: the Eurocord experience from 78 transplants. Eurocord Transplant group.Bone Marrow Transplant. 1998; 21: S59-S62PubMed Google Scholar]. Although in patient 2, the UCB nucleated cells would have been sufficient to secure engraftment without the addition of BM cells, we chose to combine UCB and BM to increase the cell dose because of the limited and not encouraging experience with UCBT in patients with X-CGD patients [32Mochizuki K. Kikuta A. Ito M. et al.Successful unrelated cord blood transplantation for chronic granulomatous disease: a case report and review of the literature.Ped Transplant. 2009; 13: 384-389Crossref PubMed Scopus (17) Google Scholar]. However, BM harvest, especially from a pediatric donor, is an invasive procedure and should be chosen only after UCB collection or transplantation fails. In such cases, we recommend delaying transplantation until the donor is between the ages of 12-24 months. Within this age range, depending on the recipient's weight, a reduced BM volume not exceeding 15 mL/kg donor weight should suffice. Alternative strategies pursued to obtain a high rate of engraftment in the presence of insufficient UCB include coinfusion of third-party mesenchymal stem cells [35Macmillan M.L. Blazar B.R. DeFor T.E. et al.Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: results of a phase I-II clinical trial.Bone Marrow Transplant. 2009; 43: 447-454Crossref PubMed Scopus (194) Google Scholar] or mobilized CD34+ cells [36Bautista G. Cabrera J.R. Regidor C. et al.Cord blood transplants supported by co-infusion of mobilized hematopoietic stem cells from a third-party donor.Bone Marrow Transplant. 2009; 43: 365-373Crossref PubMed Scopus (87) Google Scholar]. However, the available data are insufficient to offer such a strategy as an alternative to BM cells obtained from the same donor to increase the engraftment potential of the UCB graft.In conclusion, transplant physicians should be aware of the feasibility and efficacy of the PGD/HLA typing method as well as the indications of its use. Regardless of the final decision, an immediate search for a suitable unrelated donor at the time of establishing the indication for HSCT should never be omitted. IntroductionX-linked chronic granulomatous disease (X-CGD) is an inherited defect in phagocyte nicotinamide adenine dinucleotide phosphate oxidase resulting from a deficiency of gp91phox component. At the molecular level, X-CGD is caused by mutations affecting the CYBB gene on chromosome Xp21.1 [1Heyworth P.G. Cross A.R. Curnutte J.T. Chronic granulomatous disease.Curr Opin Immunol. 2003; 15: 578-584Crossref PubMed Scopus (332) Google Scholar, 2Segal B.H. Leto T.L. Gallin J.I. et al.Genetic, biochemical, and clinical features of chronic granulomatous disease.Medicine (Baltimore). 2000; 79: 170-200Crossref PubMed Scopus (720) Google Scholar]. As a result of impaired phagocytic ability, affected persons suffer from severe recurrent infections, both bacterial and fungal, resulting in the formation of infiltrating granulomatous lesions. Despite prophylactic therapy, long-term survival remains poor; only 50% of patients are alive at the age of 30 years [3Van den Berg J.M. van Koppen E. Ǻhlin A. et al.Chronic granulomatous disease: The European experience.PLoS ONE. 2009; 4 (e5234:1–10)Crossref Scopus (497) Google Scholar, 4Winkelstein J.A. Marino M.C. Johnston Jr., R.B. et al.Chronic granulomatous disease. Report on a national registry of 368 patients.Medicine (Baltimore). 2000; 79: 155-169Crossref PubMed Scopus (1223) Google Scholar]. Allogeneic hematopoietic stem cell transplantation (HSCT) using an HLA-matched sibling donor (MSD) has achieved long-term cure of X-CGD in 80% to 90% of cases [5Seger R.A. Güngor T. Belohradsky B.H. et al.Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000.Blood. 2002; 100: 4344-4350Crossref PubMed Scopus (226) Google Scholar, 6Seger R.A. Modern management of chronic granulomatous disease.Br J Haematol. 2008; 140: 255-266Crossref PubMed Scopus (194) Google Scholar]. A healthy MSD is not available in the vast majority of the cases, however. For such patients, a matched unrelated donor (MUD) is a suitable option, but at the cost of increased teatment-related morbidity and mortality (TRM) [5Seger R.A. Güngor T. Belohradsky B.H. et al.Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000.Blood. 2002; 100: 4344-4350Crossref PubMed Scopus (226) Google Scholar, 7Del Giudice I. Iori A.P. Mengarelli A. et al.Allogeneic stem cell transplant from HLA-identical sibling for chronic granulomatous disease and review of the literature.Ann Hematol. 2003; 82: 189-192PubMed Google Scholar]. Preimplantation genetic diagnosis (PGD) for single-gene diseases was developed to help families desiring a new pregnancy to select unaffected embryos in vitro, thereby avoiding the need for pregnancy termination. Recently, this strategy has been combined with HLA typing with the aim of selecting suitable histocompatible embryos as potential stem cell donors for affected siblings [8Fiorentino F. Biricik A. Karadayi H. et al.Development and clinical application of a strategy for preimplantation genetic diagnosis of single gene disorders combined with HLA matching.Mol Hum Reprod. 2004; 10: 445-460Crossref PubMed Scopus (70) Google Scholar, 9Van de Velde H. Georgiou I. De Rycke M. et al.Novel universal approach for preimplantation genetic diagnosis of β-thalassemia in combination with HLA matching of embryos.Hum Reprod. 2004; 19: 700-708Crossref PubMed Scopus (92) Google Scholar, 10Kuliev A. Rechitsky S. Tur-Kaspa I. et al.Preimplantation genetics. Improving access to stem cell therapy.Ann N Y Acad Sci. 2005; 1054: 223-227Crossref PubMed Scopus (47) Google Scholar]. There is limited experience with this methodology and even less with its completed clinical application, however." @default.
• W2000722847 created "2016-06-24" @default.
• W2000722847 creator A5004852145 @default.
• W2000722847 creator A5013344372 @default.
• W2000722847 creator A5025396979 @default.
• W2000722847 creator A5027484965 @default.
• W2000722847 creator A5027741389 @default.
• W2000722847 creator A5028985599 @default.
• W2000722847 creator A5041924392 @default.
• W2000722847 creator A5051054126 @default.
• W2000722847 creator A5051896775 @default.
• W2000722847 creator A5054592811 @default.
• W2000722847 creator A5056024008 @default.
• W2000722847 creator A5068914374 @default.
• W2000722847 creator A5071837502 @default.
• W2000722847 creator A5080546178 @default.
• W2000722847 creator A5080629810 @default.
• W2000722847 date "2010-03-01" @default.
• W2000722847 modified "2023-10-16" @default.
• W2000722847 title "Successful Hematopoietic Stem Cell Transplantation in 2 Children with X-Linked Chronic Granulomatous Disease from Their Unaffected HLA-Identical Siblings Selected Using Preimplantation Genetic Diagnosis Combined with HLA Typing" @default.
• W2000722847 cites W1568037402 @default.
• W2000722847 cites W1984539609 @default.
• W2000722847 cites W1997972990 @default.
• W2000722847 cites W1998889925 @default.
• W2000722847 cites W2008981570 @default.
• W2000722847 cites W2009382439 @default.
• W2000722847 cites W2010055592 @default.
• W2000722847 cites W2014974498 @default.
• W2000722847 cites W2031338363 @default.
• W2000722847 cites W2038413306 @default.
• W2000722847 cites W2038753879 @default.
• W2000722847 cites W2048355153 @default.
• W2000722847 cites W2057480280 @default.
• W2000722847 cites W2058062950 @default.
• W2000722847 cites W2066672702 @default.
• W2000722847 cites W2070535039 @default.
• W2000722847 cites W2075937326 @default.
• W2000722847 cites W2083978500 @default.
• W2000722847 cites W2085616796 @default.
• W2000722847 cites W2092067624 @default.
• W2000722847 cites W2110955790 @default.
• W2000722847 cites W2111504689 @default.
• W2000722847 cites W2119115947 @default.
• W2000722847 cites W2119324304 @default.
• W2000722847 cites W2127433915 @default.
• W2000722847 cites W2129413349 @default.
• W2000722847 cites W2133947529 @default.
• W2000722847 cites W2141748118 @default.
• W2000722847 cites W2148629244 @default.
• W2000722847 cites W2153788295 @default.
• W2000722847 cites W2171112980 @default.
• W2000722847 cites W2171815371 @default.
• W2000722847 cites W2405223247 @default.
• W2000722847 cites W2761397801 @default.
• W2000722847 doi "https://doi.org/10.1016/j.bbmt.2009.10.010" @default.
• W2000722847 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19835970" @default.
• W2000722847 hasPublicationYear "2010" @default.
• W2000722847 type Work @default.
• W2000722847 sameAs 2000722847 @default.
• W2000722847 citedByCount "26" @default.
• W2000722847 countsByYear W20007228472012 @default.
• W2000722847 countsByYear W20007228472013 @default.
• W2000722847 countsByYear W20007228472014 @default.
• W2000722847 countsByYear W20007228472015 @default.
• W2000722847 countsByYear W20007228472016 @default.
• W2000722847 countsByYear W20007228472017 @default.
• W2000722847 countsByYear W20007228472020 @default.
• W2000722847 countsByYear W20007228472021 @default.
• W2000722847 countsByYear W20007228472022 @default.
• W2000722847 crossrefType "journal-article" @default.
• W2000722847 hasAuthorship W2000722847A5004852145 @default.
• W2000722847 hasAuthorship W2000722847A5013344372 @default.
• W2000722847 hasAuthorship W2000722847A5025396979 @default.
• W2000722847 hasAuthorship W2000722847A5027484965 @default.
• W2000722847 hasAuthorship W2000722847A5027741389 @default.
• W2000722847 hasAuthorship W2000722847A5028985599 @default.
• W2000722847 hasAuthorship W2000722847A5041924392 @default.
• W2000722847 hasAuthorship W2000722847A5051054126 @default.
• W2000722847 hasAuthorship W2000722847A5051896775 @default.
• W2000722847 hasAuthorship W2000722847A5054592811 @default.
• W2000722847 hasAuthorship W2000722847A5056024008 @default.
• W2000722847 hasAuthorship W2000722847A5068914374 @default.
• W2000722847 hasAuthorship W2000722847A5071837502 @default.
• W2000722847 hasAuthorship W2000722847A5080546178 @default.
• W2000722847 hasAuthorship W2000722847A5080629810 @default.
• W2000722847 hasBestOaLocation W20007228471 @default.
• W2000722847 hasConcept C114538912 @default.
• W2000722847 hasConcept C126322002 @default.
• W2000722847 hasConcept C142724271 @default.
• W2000722847 hasConcept C147483822 @default.
• W2000722847 hasConcept C188280979 @default.
• W2000722847 hasConcept C203014093 @default.
• W2000722847 hasConcept C2777408962 @default.
• W2000722847 hasConcept C2778175462 @default.
• W2000722847 hasConcept C2779134260 @default.
• W2000722847 hasConcept C2781209916 @default.
• W2000722847 hasConcept C2909496165 @default.
• W2000722847 hasConcept C2911091166 @default.

• next